Halometasone | CAS#50629-82-8 | corticosteroid

Halometasone
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585158

CAS#: 50629-82-8

Description: Halometasone is a corticosteroid used in the treatment of skin disorders such as chronic eczema.

Chemical Structure

Halometasone

CAS# 50629-82-8

Instruction

Theoretical Analysis

MedKoo Cat#: 585158
Name: Halometasone
CAS#: 50629-82-8
Chemical Formula: C22H27ClF2O5
Exact Mass: 444.15
Molecular Weight: 444.900
Elemental Analysis: C, 59.39; H, 6.12; Cl, 7.97; F, 8.54; O, 17.98

Price and Availability

Size	Price	Availability
5mg	USD 350	2 Weeks
10mg	USD 650	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Halometasone; Sicorten

IUPAC/Chemical Name: Pregna-1,4-diene-3,20-dione, 2-chloro-6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6alpha,11beta,16alpha)-

InChi Key: GGXMRPUKBWXVHE-MIHLVHIWSA-N

InChi Code: InChI=1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1

SMILES Code: C[C@@]12[C@](C(CO)=O)(O)[C@H](C)C[C@@]1([H])[C@]3([H])C[C@H](F)C4=CC(C(Cl)=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 444.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Maiti R, Sirka CS, Shaju N, Hota D. Halometasone monohydrate (0.05%) in occupational contact dermatitis. Indian J Pharmacol. 2016 Mar-Apr;48(2):128-33. doi: 10.4103/0253-7613.178823. PubMed PMID: 27127314; PubMed Central PMCID: PMC4825427.

2: The Execare Working Group. Halometasone 0.05% cream in eczematous dermatoses. J Clin Aesthet Dermatol. 2013 Nov;6(11):39-44. PubMed PMID: 24307924; PubMed Central PMCID: PMC3848651.

3: Li Y, Xu W, Li L. Efficacy and Safety of Halometasone Cream to Treat Chronic Generalized Eczema and the Effects of Halometasone Cream on Serum Cortisol Levels. Biomed Res Int. 2017;2017:3265024. doi: 10.1155/2017/3265024. Epub 2017 Nov 9. PubMed PMID: 29250537; PubMed Central PMCID: PMC5700510.

4: Gao L, Qian L, Wang L, Li K, Yin R, Wang Y, Kang H, Song W, Wang G. Topical Halometasone Reduces Acute Adverse Effects Induced by Pulsed Dye Laser for Treatment of Port Wine Stain Birthmarks. J Lasers Med Sci. 2018 Winter;9(1):19-22. doi: 10.15171/jlms.2018.05. Epub 2017 Dec 26. PubMed PMID: 29399306; PubMed Central PMCID: PMC5775950.

5: Jerajani HR, Kumar AS, Kuruvila M, Nataraja HV, Philip M, Pratap DV, Sumathy TK, Krishnankutty B, Dhawan S, Thomas D. Efficacy and safety of topical halometasone in eczematous dermatoses in Indian population: an open label, noncomparative study. Indian J Dermatol. 2011 Nov;56(6):652-6. doi: 10.4103/0019-5154.91822. PubMed PMID: 22345764; PubMed Central PMCID: PMC3276890.

6: Herz G, Yawalkar SJ, Weirich EG. Evaluation of halometasone ointment in the treatment of paediatric patients with chronic eczematous dermatoses. J Int Med Res. 1983;11 Suppl 1:21-5. PubMed PMID: 6339288.

7: Pratap DV, Philip M, Rao NT, Jerajani HR, Kumar SA, Kuruvila M, Moodahadu LS, Dhawan S. Evaluation of Efficacy, Safety, and Tolerability of Fixed Dose Combination (FDC) of Halometasone 0.05% and Fusidic Acid 2% W/W Topical Cream Versus FDC of Betamethasone Valerate 0.12% and Neomycin Sulphate 0.5% W/W Topical Cream in the Treatment of Infected Eczematous Dermatosis in Indian Subjects: A Randomized Open-Label Comparative Phase III Multi-Centric Trial. Indian J Dermatol. 2013 Mar;58(2):117-23. doi: 10.4103/0019-5154.108041. PubMed PMID: 23716800; PubMed Central PMCID: PMC3657210.

8: Goswami N, Gupta VR, Jogia HA. Development and Validation of a Novel Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Halometasone, Fusidic Acid, Methylparaben, and Propylparaben in Topical Pharmaceutical Formulation. Sci Pharm. 2013 Apr-Jun;81(2):505-18. doi: 10.3797/scipharm.1301-21. Epub 2013 Feb 25. PubMed PMID: 23833716; PubMed Central PMCID: PMC3700078.

9: Yawalkar SJ, Macarol V, Montanari C. An overview of international clinical trials with halometasone cream. J Int Med Res. 1983;11 Suppl 1:1-7. PubMed PMID: 6339286.

10: Maeder E, Schindléry C, Macarol V, Schoenenberger PM. A comparative multicentre trial of halometasone/triclosan cream and diflucortolone valerate/chlorquinaldol cream in the treatment of acute dermatomycoses. J Int Med Res. 1983;11 Suppl 1:48-52. PubMed PMID: 6339293.

11: Fabry H, Yawalkar SJ. A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis. J Int Med Res. 1983;11 Suppl 1:26-30. PubMed PMID: 6339289.

12: Weitgasser H, Yawalkar SJ. Clinical evaluation on the long-term use of halometasone ointment in chronic eczema and psoriasis. J Int Med Res. 1983;11 Suppl 1:34-7. PubMed PMID: 6339291.

13: Ulrich R, Andresen I. [Treatment of acute episodes of atopic dermatitis. Double-blind comparative study with 0.05% halometasone cream versus 0.25% prednicarbate cream]. Fortschr Med. 1991 Dec 20;109(36):741-4. German. PubMed PMID: 1778534.

14: Xu W, Li Y, Chen Z, Liu T, Wang S, Li L. Wet-wrap therapy with halometasone cream for severe adult atopic dermatitis. Postgrad Med. 2018 Jun;130(5):470-476. doi: 10.1080/00325481.2018.1478108. Epub 2018 May 28. PubMed PMID: 29768078.

15: Yawalkar SJ, Macarol V, Montanari C. An overview of international clinical trials with halometasone ointment in chronic eczematous dermatoses. J Int Med Res. 1983;11 Suppl 1:13-20. PubMed PMID: 6339287.

16: Meyer E, Smith EW, Haigh JM, Kanfer I. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay. Arzneimittelforschung. 1988 Dec;38(12):1840-3. PubMed PMID: 3245859.

17: Abdel Aal H, Abdallah MA, Iskandar IO, Salama NR. Clinical experience with 0.05% halometasone/1% triclosan cream in the treatment of acute infected and infection-prone eczema in Egypt. J Int Med Res. 1987 Nov-Dec;15(6):383-90. PubMed PMID: 3325321.

18: Blum G, Yawalkar SJ. Evaluation of halometasone cream in the treatment of paediatric patients with acute eczematous dermatoses. J Int Med Res. 1983;11 Suppl 1:8-12. PubMed PMID: 6339295.

19: Galbiati G, Bonfacini V, Candiani F. Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris. J Int Med Res. 1983;11 Suppl 1:31-3. PubMed PMID: 6339290.

20: Li L, Liang Y, Hong J, Lan L, Xiao H, Xie Z. The effectiveness of topical therapy combined with 308-nm excimer laser on vitiligo compared to excimer laser monotherapy in pediatric patients. Pediatr Dermatol. 2019 Jan;36(1):e53-e55. doi: 10.1111/pde.13726. Epub 2018 Dec 5. PubMed PMID: 30520111.

Your view history

Halometasone featured